Research Article - Virology Research Journal (2021) Volume 5, Issue 5
The Effect of Ezetimibe in the Treatment of Ebola.
In this article, we are looking for treatment for Ebolavirus.We will do it using a cholesterol-lowering
drug called Ezetimibe.Marburg and Ebola hemorrhagic fevers are severe, systemic viral diseases
affecting humans and non-human primates. They are characterized by multiple symptoms such as
hemorrhages, fever, headache, muscle and abdominal pain, chills, sore throat, nausea, vomiting and
diarrhea. Elevated liver-associated enzyme levels and coagulopathy are also associated with these
diseases. Marburg and Ebola hemorrhagic fevers are caused by (Lake victoria) Marburg virus and
different species of Ebola viruses, respectively. They are enveloped, single-stranded RNA viruses and
belong to the family of filoviridae. Case fatality rates of filovirus disease outbreaks are among the
highest reported for any human pathogen, ranging from 25 to 90% or more. But when Ezetimibe is
given to patients with the Ebola virus, we see that the drug blocks the transmission of the virus to the
body by delivering the virus to the immune system.Ezetimibe has a higher affinity for NPC1L1
receptor than cholesterol, and cholesterol has a higher affinity for NPC1L1 receptor than Ebola virus .
In fact, if we want to show the percentage of desire for NPC1L1 receptor, it is as follows:
Ezetimibe> Cholesterol> Ebola virus Author(s): Ali Khanifar